Mocetinostat In Combination With Vidaza Shows High Activity In MDS Patients ...

22-01-2014 The MDS BeaconComments (0)

Mirati TherapeuticsPharmaceutical

Mocetinostat, which is being developed by the pharmaceutical company Mirati Therapeutics (NASDAQ:​MRTX), belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors. These drugs work by increasing the production of proteins that slow ...

Read more on The MDS Beacon

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top